cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bridgebio Pharma Inc
8 own
13 watching
Current Price
$10.86
$-0.26
(-2.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,622.13M
52-Week High
52-Week High
12.6378
52-Week Low
52-Week Low
4.98
Average Volume
Average Volume
1.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,622.13M
icon52-Week High12.6378
icon52-Week Low4.98
iconAverage Volume1.71M
iconDividend Yield--
iconP/E Ratio--
What does the Bridgebio Pharma Inc do?
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing BBP-418, a substrate supplementation therapy for the treatment of limb-girdle muscular dystrophy type 2i. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Read More
How much money does Bridgebio Pharma Inc make?
News & Events about Bridgebio Pharma Inc.
Ticker Report
26days ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO Get Rating) CEO Neil Kumar sold 120,000 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $7.67, for a total value of $920,400.00. Following the transaction, the chief ...
Zolmax
27days ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO Get Rating)s share price fell 5.9% on Friday following insider selling activity. The stock traded as low as $7.21 and last traded at $7.23. 6,504 shares were traded during trading, a decline of 99% from the average session volume of 1,121,127 shares. The stock had...
Globe Newswire
1month ago
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan...
Benzinga
1month ago
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else? read more...
Globe Newswire
1month ago
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1) - The ...
Frequently Asked Questions
Frequently Asked Questions
What is Bridgebio Pharma Inc share price today?
plus_minus_icon
Can Indians buy Bridgebio Pharma Inc shares?
plus_minus_icon
How can I buy Bridgebio Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Bridgebio Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bridgebio Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Bridgebio Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Bridgebio Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bridgebio Pharma Inc?
plus_minus_icon
What percentage is Bridgebio Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bridgebio Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.86
$-0.26
(-2.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.08
$-1.27 (-5.01 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.51
$-0.65 (-3.07 %)
Replimune Group Inc
Replimune Group Inc
$28.29
$-0.80 (-2.75 %)
Travere Therapeutics Inc
Travere Therapeutics Inc
$21.72
$-0.83 (-3.68 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.08
$-1.27 (-5.01 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.51
$-0.65 (-3.07 %)
Replimune Group Inc
Replimune Group Inc
$28.29
$-0.80 (-2.75 %)
Travere Therapeutics Inc
Travere Therapeutics Inc
$21.72
$-0.83 (-3.68 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00